An aging population, rising rates of diabetes and obesity -- along with limited access to care for some -- continue to fuel the incidence of heart disease. However, the way medicine prevents and ...

This review evaluates the safety profile of glucagon-like peptide-1 receptor agonists and related incretin therapies used for obesity and type 2 diabetes. It highlights common gastrointestinal effects ...

A quick look at the composition of some cultured dairy products shows that they are well designed for GLP-1 diets. High-protein yogurts, including skyr and Greek yogurt, are the first products that ...

The risk for nonscarring hair loss (NSHL) is increased in association with glucagon-like peptide-1 receptor agonist (GLP-1 RA ...

This article was reviewed by Darragh O’Carroll, MD. Key Takeaways: GLP-1s are used for type 2 diabetes, as well as weight loss in people with obesity ...

Treating kidney disease GLP-1s show higher risk than SGLT2 inhibitors in kidney outcomes, but lower albuminuria and mortality rates.

The 83-year-old made the health admission during the Feb. 18 episode of ‘The View’ ...

There has been increased interest in over-the-counter GLP-1 patches. If you’re thinking about using, here’s what you should know.

The online pharmacy is collaborating with a digital health provider to combine direct-to-patient GLP-1 dispensing with virtual clinical support, highlighting evolving supply chain and regulatory ...

GLP-1 weight loss drugs have quickly moved from medical journals to household conversations, reshaping how Americans think about obesity, diabetes and weight loss. Headlines often describe them as ...

Demand for GLP-1 drugs continues to climb, boosted by a major price drop and the FDA’s approval of an oral Wegovy pill that has already generated more than 26,000 prescriptions in January.

Viking Therapeutics (VKTX +4.90%) is aiming to join one of the biggest growth industries of the times: the weight loss drug ...